This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Bloomberg – Mylan’s Pay for CEO Bresch Grates on Lawmakers, Many Investors
September 22, 2016
Mylan NV faces intense scrutiny from lawmakers after the company raised the price of its EpiPen allergy shot. Robin Ferracone, CEO of Farient Advisors, comments on CEO Heather Bresch’s Say on Pay record and how it reflects on governance.
Read on Bloomberg© 2024 Farient Advisors LLC. | Privacy Policy | Site by: Treacle Media